title: Long-Term Tumor Control despite Late Pseudoprogression on(18)F-FDG-PET following Extremely Hypofractionated Stereotactic Radiotherapy for Retropharyngeal Lymph Node Metastasis from Esthesioneuroblastoma.
abstract: (18)F-FDG-PET is a valuable adjunct to conventional imaging for evaluating treatment response following stereotactic body radiotherapy (SBRT) for head and neck malignancies (HNM). The effect of treatment-related inflammation is generally deemed negligible after 12 weeks following conventionally fractionated radiotherapy. Herein, we describe an unusual case showing pseudoprogression on (18)F-FDG-PET 2 years after SBRT for retropharyngeal lymph node metastasis (RPLNm) from esthesioneuroblastoma. A 36-year-old man presented with right RPLNm 32 months after the diagnosis of esthesioneuroblastoma associated with ectopic adrenocorticotropic hormone production. The RPLNm was treated with SBRT in 2 fractions over 8 days using dynamic conformal arcs with concomitant chemotherapy with cisplatin and etoposide. Although follow-up MRI showed sustained lesion regression, the early/delayed maximum standardized uptake (SUVmax) values on dual-time-point (18)F-FDG-PET obtained 1 and 2 years after SBRT were 7.7/8.3 and 8.5/10.1, respectively, suggesting local progression. Despite no subsequent focal or systemic treatment, the SUVmax values gradually decreased thereafter over a period of 4 years (3.3/3.4 at 76 months). MRI obtained 7 years after SBRT revealed sustained tumor regression. No obvious relevant toxicities have occurred. Thus, caution should be exercised in the interpretation of the SUVmax change following ablative irradiation for HNM.
authors.affiliation: Department of Radiation Oncology, Murakami Memorial Hospital, Asahi University, Gifu, Japan.
authors.forename: Kazuhiro
authors.initials: K
authors.lastname: Ohtakara
authors.affiliation: Department of Radiology, Gifu University Graduate School of Medicine, Gifu, Japan.
authors.forename: Hiroaki
authors.initials: H
authors.lastname: Hoshi
keywords: 18F-FDG-PET; Esthesioneuroblastoma; Pseudoprogression; Retropharyngeal lymph node metastasis; Stereotactic body radiotherapy